BioCentury
ARTICLE | Company News

Eisai sales and marketing update

August 3, 2015 7:00 AM UTC

Eisai launched Lenvima lenvatinib in the U.K. to treat patients with radioactive iodine refractory differentiated thyroid cancer. The compound is an inhibitor of multiple VEGF receptor tyrosine kinas...